PMID- 8322560
OWN - NLM
STAT- MEDLINE
DCOM- 19930804
LR  - 20190814
IS  - 0001-5172 (Print)
IS  - 0001-5172 (Linking)
VI  - 37
IP  - 4
DP  - 1993 May
TI  - Effects of high dose E. coli lipopolysaccharide on rabbit lung function, and of 
      subsequent addition of chemotactic granulocyte activators to their isolated, 
      blood-perfused lungs.
PG  - 334-42
AB  - E. coli LPS was infused (1 microgram/kg to 5 mg/kg over 30 min) to spontaneously 
      breathing rabbits, and their arterial blood pressure (ABP), blood leukocyte count 
      and blood gases were observed for 2.5-3.5 h. Pulmonary vascular and airway 
      function were subsequently evaluated in vitro by comparing weight changes, fluid 
      filtration rates, pulmonary vascular resistance (PVR) and airway pressures in 
      their isolated, blood-perfused lungs with those in lungs from untreated rabbits. 
      Lung preparations from both groups of animals were then exposed to autologous 
      zymosan-activated plasma (ZAP) or n-formyl-methionyl-leucyl-phenylalanine (FMLP) 
      and perfused for 2 more hours. LPS addition to isolated rabbit leukocytes 
      increased cell aggregation; cell chemiluminescence after activation with FMLP was 
      also enhanced. Infusion of 1-5 mg/kg LPS decreased the count of all types of 
      leukocytes and caused a metabolic acidosis (BE < -8 mmol), but no decrease in 
      ABP. PAO2-Pao2 increased by about 2.0 kPa. No vascular permeability increase was 
      detected in the lungs of these animals during subsequent in vitro perfusion. 
      Addition of ZAP or FMLP during perfusion markedly increased the PVR in lungs from 
      LPS animals, but did not induce major microvascular leakage. No significant 
      differences in edema between lungs from LPS-treated and control animals were 
      found by microscopy.
FAU - Opdahl, H
AU  - Opdahl H
AD  - Department of Physiology, University of Oslo, Norway.
FAU - Mollnes, T E
AU  - Mollnes TE
FAU - Naess, O
AU  - Naess O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Chemotactic Factors)
RN  - 0 (Complement Membrane Attack Complex)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Reactive Oxygen Species)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 9010-72-4 (Zymosan)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects/physiology
MH  - Capillary Permeability/drug effects
MH  - Cell Movement
MH  - Chemotactic Factors/*pharmacology
MH  - Complement Membrane Attack Complex/analysis
MH  - *Escherichia coli
MH  - Female
MH  - Leukocyte Count/drug effects
MH  - Lipopolysaccharides/administration & dosage/*pharmacology
MH  - Luminescent Measurements
MH  - Lung/blood supply/*drug effects/pathology/physiopathology
MH  - Male
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/*drug effects/immunology/physiology
MH  - Organ Size
MH  - Oxygen/blood
MH  - Pulmonary Alveoli/pathology
MH  - Rabbits
MH  - Reactive Oxygen Species/metabolism
MH  - Vascular Resistance/drug effects
MH  - Zymosan/pharmacology
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 10.1111/j.1399-6576.1993.tb03725.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 1993 May;37(4):334-42. doi: 
      10.1111/j.1399-6576.1993.tb03725.x.